ShortCuts-This Week in the Journals

October 29, 2007
ShortCuts-This Week in the Journals

Commentary by Michael Poles MD, Associate Editor, Clinical Correlations

This week seems like a continuation of last week in a couple of ways. Last week our Editor-In-Chief, Dr. Neil Shapiro, wrote about the epidemic of MRSA. This hit closer to home when it was reported in the lay-press that a 12-year old Brooklyn student died of an overwhelming MRSA infection that arose from a skin lesion. I implore all physicians to consider the effect of indiscriminate use of antibiotics. Furthermore, perhaps it is…

Read more »

Inpatient Diabetes Management: Case 5

October 25, 2007
Inpatient Diabetes Management: Case 5

Commentary by Mary Vouyiouklis MD, Fellow, and Ann Danoff MD, Director, Division of Endocrinology, Diabetes and Metabolism, NYU Medical Center

Welcome to Case 5 of our special diabetes series intended to highlight the essentials of diabetes care in the inpatient setting. Over the last several weeks, we have been presenting individual cases followed by some management questions and answers.

Case 5: The Case of Ms. Samson

Ms. Samson is a 55 year-old woman with Lupus who was admitted to the hospital with a…

Read more »

FDA Approves Label Revision for Erectile Dysfunction Drugs

October 24, 2007
FDA Approves Label Revision for Erectile Dysfunction Drugs

Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident

On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) inhibitors. This includes drugs Cialis®, Levitra®, Viagra®, as well as Revatio®, a PDE-5 inhibitor indicated for pulmonary arterial hypertension (PAH). The label revisions draw attention to the potential risk of sudden hearing loss, sometimes associated with vestibular symptoms such as tinnitus, vertigo, and dizziness. Based on 29 postmarketing reports of this incidence,…

Read more »

ShortCuts-This Week in the Journals

October 22, 2007
ShortCuts-This Week in the Journals

Commentary by Neil Shapiro MD, Editor-In-Chief, Clinical Correlations

As fall begins in earnest and the leaves start to change we find a diverse group of articles that make the cut and a few that didn’t quite make it but should remain on your radar screen…

Suburban parents were panicked this week by the media portraying the end of the world coming in the form of community acquired MRSA. The explosion of media interest stems from a CDC report released this week outlining…

Read more »

Clinical Pathology Conference 10/12/07-The Answer

October 19, 2007

Case Presentation by Elizabeth Ross, MD, Chief Resident

Please review the posting of last week’s CPC here.

When you’re ready you can download the CPC Answer.

Read more »

Class Act: Relieving the Obstruction – Surgical Approaches to the Management of Obstructive Sleep Apnea

October 18, 2007
Class Act: Relieving the Obstruction – Surgical Approaches to the Management of Obstructive Sleep Apnea

Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our students in the clinics or on the wards. Prior to publication, each commentary is thoroughly reviewed for content by a faculty member. Enjoy…

Commentary by Andrew Kleinberger, NYU Medical Student

Obstructive Sleep Apnea (OSA) is a syndrome of sleep-disordered breathing that has gained a great deal of attention…

Read more »

Clinical Pharmacy Corner: How Do Sulfonylureas Work?

October 17, 2007
Clinical Pharmacy Corner: How Do Sulfonylureas Work?

Commentary by Helen Kourlas, PharmD and John Papadopoulas, PharmD, Pharmacology Section Editors

The sulfonylureas are members of a class of substituted arylsulfonylureas that have been used clinically since the 1950s. These agents are usually divided into two categories or generations. First generation agents include acetohexamide, chlorpropamide, tolazamide, and tolbutamide (the first widely utilized agent). The more potent second-generation agents include glimepiride, glipizide, and glyburide.

Sulfonylureas acutely lower plasma glucose by stimulating the release of insulin. The primary mechanism is through binding to sulfonylurea receptors (SUR-1)…

Read more »

ShortCuts-This Week in the Journals

October 15, 2007
ShortCuts-This Week in the Journals

Commentary by Sean Cavanaugh MD, Associate Editor, Clinical Correlations

Moving through the journals this week, it is all about primary care.

There was an interesting article for Primary Care MDs in this week’s NEJM.  A long term follow-up of the West of Scotland Coronary Prevention Study, which compared pravastatin vs placebo in the primary prevention of coronary artery disease, demonstrated a durable decrease in events even after the treatment groups re-approximated each other.  A succinct conclusion is that 5 years of treatment…

Read more »